在未经治疗的基本高血压患者中,HAMSAB的益生菌干预在II期随机试验中进行了评估
Hamdi A Jama1, Dakota Rhys-Jones1,2, Michael Nakai1
1Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, Clayton, VIC, Australia.
Nature cardiovascular research
|August 28, 2024
概括
益生菌HAMSAB补充剂通过增加有益的短链脂肪酸 (SCFA) 有效降低了高血压患者的缩血压. 这种干预措施在治疗基本高血压方面表现有前途.
科学领域:
- 微生物学 微生物学
- 营养科学 营养科学
- 心血管研究研究心血管研究
背景情况:
- 食纤维由肠道微生物群发酵成短链脂肪酸 (SCFA),如酸盐和丁酸盐.
- 在实验环境中,SCFA已经显示出降血压的作用,但其临床相关性尚不清楚.
研究的目的:
- 研究使用乙化和丁化高氨糖玉米粉 (HAMSAB) 降低血压的益生菌干预的有效性.
- 评估HAMSAB对循环细胞因子,免疫标记物和肠道微生物组合的影响.
主要方法:
- 一项II期,随机,安慰剂控制,双盲交叉试验,涉及20名未经治疗的高血压参与者.
- 参与者接受了40g/day的HAMSAB或安慰剂3周的时间,分开3周的洗.
- 主要终点是走动系统血压的降低;次要终点包括微生物组和免疫标志物的变化.
主要成果:
- 补充HAMSAB导致24小时缩血压的临床显著降低,无论参与者的人口统计学.
- 在HAMSAB治疗组期间没有报告任何不良反应.
- 汉姆萨布增加了循环中的酸盐和丁酸盐水平,调节了肠道微生物群,并增强了SCFA产生细菌.
结论:
- 益生菌HAMSAB补充剂是一种潜在的有效策略,可以在患有基本高血压的人中提供SCFA并降低血压.
- 这种干预提供了一种有希望的,安全的,没有不利影响的方法,通过肠道微生物组调节来管理高血压.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
142
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
142